CALL/NOVO-NORDISK B/1400/0.01/20.06.25 | Market Closed - BOERSE MUENCHEN 13:27:07 05/06/2024 BST | ||
| 0.042 EUR | +2.44% |
|
| Current month | +10.53% | ||
| 1 month | +40.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 0.042 | +2.44% |
| 04/06/24 | 0.041 | +7.89% |
| 03/06/24 | 0.038 | 0.00% |
| 31/05/24 | 0.038 | -5.00% |
| 30/05/24 | 0.04 | +5.26% |
Real-time BOERSE MUENCHEN
Last update June 05, 2024 at 01:27 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG7D9Q |
| ISIN | DE000GG7D9Q5 |
| Date issued | 22/04/2024 |
| Strike | 1,400 kr |
| Maturity | 20/06/2025 (380 Days) |
| Parity | 100 : 1 |
| Emission price | 0.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.042 € |
|---|---|
| Lowest since issue | 0.027 € |
| Spread | 0.01 € |
| Spread % | 19.61% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Warrants
- Warrant